Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Vanda Pharmaceuticals Inc. | d301385d8k.htm |
Exhibit 99.1
Company Contact:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(240) 599-4500
cristina.murphy@vandapharma.com
Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
ROCKVILLE, MD. – February 14, 2012 – Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational results for the fourth quarter and twelve months ended December 31, 2011.
Key Highlights:
| • | Initial clinical data in the RESET study revealed potential of tasimelteon to reset the body clock in Non-24-Hour Sleep-Wake Disorder (Non-24-Hour Disorder). |
| • | The tasimelteon Non-24-Hour Disorder program continues to advance towards a projected mid-2013 New Drug Application (NDA) filing with the U.S. Food and Drug Administration (FDA). Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012. |
| • | The tasimelteon MAGELLAN Phase IIb/III efficacy study for Major Depressive Disorder (MDD) is ongoing and Vanda expects to report top-line results in the first half of 2013. |
| • | Vanda recorded fourth quarter 2011 revenue of $8.4 million including royalties of $1.6 million. Full year 2011 Fanapt® prescriptions, as reported by IMS, exceeded 120,000, compared to approximately 55,000 for 2010. |
Page 1 of 7
FULL YEAR 2011 REPORTED RESULTS
Total revenues for the full year 2011 were $31.3 million, compared to $35.7 million for 2010. Full year 2011 revenues included $4.5 million in Fanapt® royalties received from Novartis, as compared to $3.1 million for the prior year. Both 2011 and 2010 revenues include $26.8 million recognized from the $200.0 million upfront payment previously received from Novartis for Fanapt® U.S. and Canadian rights. 2010 full year revenues also included $5.8 million in product sales to Novartis and grant revenue.
Total operating expenses for 2011 were $42.0 million, compared to $26.9 million for 2010. The primary driver of the higher expenses in 2011 was the ongoing support of the tasimelteon Non-24-Hour Disorder and MDD clinical studies.
Vanda recorded a net loss of $9.8 million for 2011, compared to net income of $7.2 million for 2010. Diluted net loss per share for 2011 was $0.35, compared to diluted net income per share of $0.25 for 2010.
Vanda’s cash, cash equivalents and marketable securities as of December 31, 2011 totaled $167.9 million.
FOURTH QUARTER 2011 REPORTED RESULTS
Total revenues for the fourth quarter of 2011 were $8.4 million, compared to $7.8 million for 2010. Fourth quarter 2011 revenues included $1.6 million in Fanapt® royalties received from Novartis as compared to royalties of $0.5 million for the fourth quarter of 2010.
Total operating expenses for the fourth quarter of 2011 were $14.3 million, compared to $7.0 million for the fourth quarter of 2010. The primary driver of the higher expenses in the fourth quarter of 2011 was the initiation and ongoing support of the tasimelteon Non-24-Hour Disorder and MDD clinical studies.
Vanda recorded a net loss of $5.5 million for the fourth quarter of 2011, compared to net income of $2.2 million for the fourth quarter of 2010. Diluted net loss per share for the fourth quarter of 2011 was $0.20, compared to diluted net income of $0.08 per share for the fourth quarter of 2010.
Full Year December 31, 2011 Key Financial Figures1
| Twelve Months Ended | ||||||||||||||||
| (in thousands, except per share amounts) | December 31 2011 |
December 31 2010 |
Change ($) |
Change (%) |
||||||||||||
| Total revenues |
$ | 31,270 | $ | 35,709 | $ | (4,439 | ) | -12 | % | |||||||
| Research & development expenses |
28,996 | 12,338 | 16,658 | 135 | % | |||||||||||
| General & administrative expenses |
11,486 | 10,147 | 1,339 | 13 | % | |||||||||||
| Non-cash stock-based compensation2 |
5,501 | 4,981 | 520 | 10 | % | |||||||||||
| Income (loss) before tax provision |
(10,246 | ) | 9,269 | (19,515 | ) | -211 | % | |||||||||
| Tax provision (benefit) |
(444 | ) | 2,077 | (2,521 | ) | -121 | % | |||||||||
| Net income (loss) |
(9,802 | ) | 7,192 | (16,994 | ) | -236 | % | |||||||||
| Diluted net income (loss) per share |
$ | (0.35 | ) | $ | 0.25 | $ | (0.60 | ) | -240 | % | ||||||
Page 2 of 7
Fourth Quarter 2011 Key Financial Figures1
| Three Months Ended | ||||||||||||||||
| (in thousands, except per share amounts) | December 31 2011 |
September 30 2011 |
Change ($) |
Change (%) |
||||||||||||
| Total revenues |
$ | 8,370 | $ | 7,969 | $ | 401 | 5 | % | ||||||||
| Research & development expenses |
10,556 | 8,174 | 2,382 | 29 | % | |||||||||||
| General & administrative expenses |
3,345 | 2,711 | 634 | 23 | % | |||||||||||
| Non-cash stock-based compensation2 |
1,318 | 1,254 | 64 | 5 | % | |||||||||||
| Loss before tax provision |
(5,809 | ) | (3,187 | ) | (2,622 | ) | -82 | % | ||||||||
| Tax benefit |
(286 | ) | (113 | ) | (173 | ) | -153 | % | ||||||||
| Net loss |
(5,523 | ) | (3,074 | ) | (2,449 | ) | -80 | % | ||||||||
| Diluted net loss per share |
$ | (0.20 | ) | $ | (0.11 | ) | $ | (0.09 | ) | -82 | % | |||||
Select Cash Flow Data1
| Twelve Months Ended | ||||||||
| (in thousands) | December 31 2011 |
December 31 2010 |
||||||
| Net cash provided by (used in) |
||||||||
| Operating activities |
(28,410 | ) | (10,898 | ) | ||||
| Investing activities |
73,749 | (155,622 | ) | |||||
| Financing activities |
25 | 3,784 | ||||||
|
|
|
|
|
|||||
| Net change in cash and cash equivalents |
$ | 45,364 | $ | (162,736 | ) | |||
|
|
|
|
|
|||||
Select Balance Sheet Data1
| (in thousands) | December 31 2011 |
September 30 2011 |
December 31 2010 |
|||||||||
| Total cash and marketable securities |
$ | 167,896 | $ | 180,459 | $ | 198,037 | ||||||
| (1) | Unaudited |
| (2) | Non-cash stock-based compensation is allocated to both Research & development and General & administrative expenses |
OPERATIONAL HIGHLIGHTS
On January 26, 2012, Vanda announced that initial clinical data in the RESET study revealed the potential of tasimelteon to reset the body clock in Non-24-Hour Disorder. The tasimelteon Non-24-Hour Disorder program continues to advance towards a projected mid-2013 NDA filing with the FDA. Vanda is in continuing discussions with the FDA to confirm the path and requirements for this regulatory submission. Vanda expects to complete the two Phase III efficacy studies, SET and RESET, by the end of 2012.
The tasimelteon MAGELLAN efficacy study for MDD is ongoing and Vanda expects to report top-line results in the first half of 2013. This Phase IIb/III study in MDD was initiated in September 2011 and is expected to enroll 500 patients across approximately 40 sites.
Full year 2011 Fanapt® prescriptions, as reported by IMS, exceeded 120,000 compared to approximately 55,000 for 2010. Vanda has been informed that Novartis is continuing the Phase II development program for the long-acting injectable formulation of Fanapt®.
Page 3 of 7
The review of Vanda’s Marketing Authorization Application (MAA) for oral iloperidone tablets in the European Union is ongoing. The European Medicines Agency (EMA) has provided its standard 120-day list of questions and has granted Vanda a 3-month extension, through mid-May 2012, for Vanda to prepare its response. After further evaluation of the regulatory and commercial environment, Vanda has no current plans to pursue registration for Fanapt® in Singapore and Australia. Regulatory filings for market approval of Fanapt® by Vanda’s commercial partners are under review in Israel, Mexico and Argentina.
CONFERENCE CALL
Vanda has scheduled a conference call for today, Tuesday, February 14, 2012, at 10:00 AM ET. During the call, Vanda’s management will discuss the fourth quarter and full year 2011 results and other corporate activities. Investors can call 866-271-0675 (domestic) and 617-213-8892 (international) and use passcode 76685033. A replay of the call will be available beginning Tuesday, February 14, 2012 at 12:00 PM ET and will be accessible until Tuesday, February 21, 2012, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 37381299.
The conference call will be broadcast simultaneously on Vanda’s website, http://www.vandapharma.com. Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations. The call will also be archived on Vanda’s website for a period of 30 days, through March 15, 2012.
ABOUT VANDA PHARMACEUTICALS INC.:
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders. For more on Vanda, please visit http://www.vandapharma.com.
Page 4 of 7
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
Various statements in this release are “forward-looking statements” under the securities laws. Words such as, but not limited to, “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” “project,” “target,” “likely,” “will,” “would,” and “could,” or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the company’s forward-looking statements include, among others: the extent and effectiveness of the development, sales and marketing and distribution support Fanapt® receives; Vanda’s ability to successfully commercialize Fanapt® outside of the U.S. and Canada; delays in the completion of Vanda’s clinical trials; a failure of Vanda’s products, product candidates or partnered products to be demonstrably safe and effective; Vanda’s failure to obtain regulatory approval for its products, product candidates or partnered products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda’s products, product candidates or partnered products in the marketplace, or a failure to become or remain profitable; Vanda’s expectations regarding trends with respect to its costs and expenses; Vanda’s inability to obtain the capital necessary to fund additional research and development activities; Vanda’s failure to identify or obtain rights to new products or product candidates; Vanda’s failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; limitations on Vanda’s ability to utilize some or all of its prior net operating losses and research and development credits; a loss of any of Vanda’s key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda’s products or product candidates under its license and sublicense agreements and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Vanda’s annual report on Form 10-K for the fiscal year ended December 31, 2010 which is on file with the SEC and available on the SEC’s website at www.sec.gov. In addition to the risks described above and in Vanda’s annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda’s results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.
All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
####
Page 5 of 7
VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
| Three Months Ended | Twelve Months Ended | |||||||||||||||
| (In thousands, except for per share amounts) | December 31 2011 |
December 31 2010 |
December 31 2011 |
December 31 2010 |
||||||||||||
| Revenues: |
||||||||||||||||
| Licensing agreement |
$ | 6,752 | $ | 6,752 | $ | 26,789 | $ | 26,789 | ||||||||
| Royalty revenue |
1,618 | 511 | 4,481 | 3,141 | ||||||||||||
| Product sales |
— | — | — | 5,290 | ||||||||||||
| Grant revenue |
— | 489 | — | 489 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total revenues |
8,370 | 7,752 | 31,270 | 35,709 | ||||||||||||
| Operating expenses: |
||||||||||||||||
| Cost of sales - product |
— | — | — | 2,891 | ||||||||||||
| Research and development |
10,556 | 3,822 | 28,996 | 12,338 | ||||||||||||
| General and administrative |
3,345 | 2,762 | 11,486 | 10,147 | ||||||||||||
| Intangible asset amortization |
377 | 377 | 1,495 | 1,495 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
14,278 | 6,961 | 41,977 | 26,871 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Income (loss) from operations |
(5,908 | ) | 791 | (10,707 | ) | 8,838 | ||||||||||
| Other income: |
||||||||||||||||
| Interest income |
99 | 142 | 461 | 431 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total other income |
99 | 142 | 461 | 431 | ||||||||||||
| Income (loss) before income tax provision (benefit) |
(5,809 | ) | 933 | (10,246 | ) | 9,269 | ||||||||||
| Tax provision (benefit) |
(286 | ) | (1,266 | ) | (444 | ) | 2,077 | |||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) |
$ | (5,523 | ) | $ | 2,199 | $ | (9,802 | ) | $ | 7,192 | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net income (loss) per share: |
||||||||||||||||
| Basic |
$ | (0.20 | ) | $ | 0.08 | $ | (0.35 | ) | $ | 0.26 | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
$ | (0.20 | ) | $ | 0.08 | $ | (0.35 | ) | $ | 0.25 | ||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Shares used in calculation of net income (loss) per share: |
||||||||||||||||
| Basic |
28,115,175 | 28,038,074 | 28,106,831 | 27,916,388 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Diluted |
28,115,175 | 28,892,347 | 28,106,831 | 28,534,617 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Page 6 of 7
VANDA PHARMACEUTICALS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)
| (In thousands) | December 31, 2011 |
December 31, 2010 |
||||||
| ASSETS |
||||||||
| Current assets: |
||||||||
| Cash and cash equivalents |
$ | 87,923 | $ | 42,559 | ||||
| Marketable securities, current |
60,961 | 155,478 | ||||||
| Accounts receivable |
1,618 | 511 | ||||||
| Prepaid expenses, deposits and other current assets |
2,999 | 1,843 | ||||||
| Deferred tax, current |
— | 182 | ||||||
|
|
|
|
|
|||||
| Total current assets |
153,501 | 200,573 | ||||||
| Marketable securities, non-current |
19,012 | — | ||||||
| Property and equipment, net |
964 | 937 | ||||||
| Other assets, non-current |
84 | — | ||||||
| Intangible asset, net |
8,027 | 9,522 | ||||||
| Deferred tax, non-current |
— | 1,639 | ||||||
| Restricted cash |
1,030 | 430 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 182,618 | $ | 213,101 | ||||
|
|
|
|
|
|||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
||||||||
| Current liabilities: |
||||||||
| Accounts payable |
$ | 996 | $ | 648 | ||||
| Accrued liabilities |
3,381 | 1,324 | ||||||
| Accrued income taxes |
— | 2,266 | ||||||
| Deferred rent, current |
453 | — | ||||||
| Deferred revenue, current |
26,789 | 26,789 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
31,619 | 31,027 | ||||||
| Non-current liabilities: |
||||||||
| Deferred rent, non-current |
461 | 490 | ||||||
| Deferred revenue, non-current |
117,064 | 143,853 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
149,144 | 175,370 | ||||||
|
|
|
|
|
|||||
| Stockholders’ equity: |
||||||||
| Common stock |
28 | 28 | ||||||
| Additional paid-in capital |
296,868 | 291,342 | ||||||
| Accumulated other comprehensive income |
21 | 2 | ||||||
| Accumulated deficit |
(263,443 | ) | (253,641 | ) | ||||
|
|
|
|
|
|||||
| Total stockholders’ equity |
33,474 | 37,731 | ||||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ equity |
$ | 182,618 | $ | 213,101 | ||||
|
|
|
|
|
|||||
SOURCE Vanda Pharmaceuticals Inc.
COMPANY CONTACT:
Cristina Murphy
Senior Communications Manager
Vanda Pharmaceuticals Inc.
(240) 599-4500
cristina.murphy@vandapharma.com
Page 7 of 7